Danaher Corporation

New Capabilities

Parent company of Masimo since June 2026

Masimo's smartSET pulse oximetry platform now detects atrial fibrillation, its second AI-powered clinical event feature after opioid-induced respiratory depression. The company announced the FDA clearance on October 17, 2026. In validation testing, the AFib feature detected suspicious rhythms with 97% sensitivity and 100% specificity.

Updated Oct 18

Money Moves

As of May 2026: Acquirer; will integrate Masimo into Diagnostics segment

Eighteen months after activist investor Politan Capital ousted Joe Kiani from the board of the medical-device company he founded in 1989, Masimo shareholders voted to sell it to Danaher for $9.9 billion. Roughly 37 million shares favored the deal; 17,061 opposed it, and 14,035 abstained.

Updated May 31